Baby formula will reportedly be in short supply well into July, though Abbott Laboratories has resumed production at its Sturgis, Michigan factory, according to a report Saturday.
In a statement, Abbott said the Michigan plant will begin producing “specialty and metabolic formulas.” Initial release of EleCare product to consumers starting June 20.”
The company will start manufacturing Similac formula and other regular products after prioritizing the specialty formulas,”with supplies hitting stores a few weeks later,” the Walls Street Journal reports citing “a person familiar with the matter”.
Part of Abbott’s statement reads:
We understand the urgent need for infant nutrition, and our number one priority is putting quality, safe infant nutrition into the hands of families across America. We will ramp up production as soon as possible while meeting all requirements. We are committed to safety and quality and will do whatever it takes to regain the trust that parents, carers and healthcare providers have placed in us for 130 years.
On February 17, Abbott announced it had initiated a voluntary recall of formula products, including EleCare, Similac and Alimentum, after consumers complained that four infants who consumed products made at the facility developed bacterial infections. The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) launched investigations into the matter, and the CDC found no link between the bacterial infections and Sturgis disease, according to a May 16 news release. Abbott laboratory.
Although the “factory had produced about one-fifth of the infant formula in the country” like that Wall Street Journal and the gap in production would impact one of the most vulnerable populations in the country, a Biden administration official claims President Joe Biden was only briefed on the crisis in April, Breitbart News reported.
On Wednesday, White House National Economic Council director Brian Deese told CNN The leadership:
We were notified by the FDA of the closure in February. And from that point forward, the FDA and all of the administrative staff in all relevant agencies in the White House worked to address the issue. One of the reasons production has increased and the companies that were here today have been able to increase production by as much as they have is that they have been working on this problem for months now. But Abbott took too long to agree to a consent decree, and once it was clear that this facility wouldn’t be back up and running sooner, it was clear we were about to face a bigger challenge. At that point, the President was informed.
Abbot announced that in its May 16 release it has reached an agreement regarding a consent decree with the FDA to resume production at the facility.